Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 3 4Phase 1/2 4Phase 2 2Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Solid Tumors 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × adagrasib × Clear all
NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

Phase 2 Recruiting
170 enrolled
Other solid neoplasm

Solid Tumors

NCT05853575 2026-03-27

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Mirati Therapeutics Inc.

Phase 2 Active not recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡